ReP USP - Resultado da busca

Artigo de periodico
Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial (2021)
Butt, Jawad H; Nicolau, Jose Carlos ; Verma, Subodh; Docherty, Kieran F; Petrie, Mark C; Inzucchi, Silvio E; Schou, Morten; Kosiborod, Mikhail N; Langkilde, Anna Maria; Martinez, Felipe A
Source: European journal of heart failure. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, GLICOSÍDEOS, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BUTT, Jawad H et al. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European journal of heart failure, v. 23, n. 4, p. 601-613, 2021Tradução . . Disponível em: https://doi.org/10.1002/ejhf.2124. Acesso em: 01 maio 2024.
APA
Butt, J. H., Nicolau, J. C., Verma, S., Docherty, K. F., Petrie, M. C., Inzucchi, S. E., et al. (2021). Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial. European journal of heart failure, 23( 4), 601-613. doi:10.1002/ejhf.2124
NLM
Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial [Internet]. European journal of heart failure. 2021 ; 23( 4): 601-613.[citado 2024 maio 01 ] Available from: https://doi.org/10.1002/ejhf.2124
Vancouver
Butt JH, Nicolau JC, Verma S, Docherty KF, Petrie MC, Inzucchi SE, Schou M, Kosiborod MN, Langkilde AM, Martinez FA. Efficacy and safety of dapagliflozin according to aetiology in heart failure with reduced ejection fraction: insights from the DAPA-HF trial [Internet]. European journal of heart failure. 2021 ; 23( 4): 601-613.[citado 2024 maio 01 ] Available from: https://doi.org/10.1002/ejhf.2124
Artigo de periodico
Cooling as an Adjunctive Therapy to Percutaneous Intervention in Acute Myocardial Infarction: COOL-MI InCor Trial (2021)
Dallan, Luis Augusto Palma; Giannetti, Natali Schiavo; Rochitte, Carlos Eduardo; Polastri, Thatiane Facholi; Martin, Claudia Yanet Bernoche San; Hajjar, Ludhmila Abrahão ; Nicolau, Jose Carlos ; Jr, Mucio Tavares de Oliveira; Dae, Michael; Silva, Expedito Eustaquio Ribeiro da; Kalil Filho, Roberto
Source: Therapeutic hypothermia and temperature management. Unidade: FM
Subjects: INFARTO DO MIOCÁRDIO, TERAPIA COMBINADA, FATORES DE RISCO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DALLAN, Luis Augusto Palma et al. Cooling as an Adjunctive Therapy to Percutaneous Intervention in Acute Myocardial Infarction: COOL-MI InCor Trial. Therapeutic hypothermia and temperature management, v. 11, n. 3, p. 135-144, 2021Tradução . . Disponível em: https://doi.org/10.1089/ther.2020.0018. Acesso em: 01 maio 2024.
APA
Dallan, L. A. P., Giannetti, N. S., Rochitte, C. E., Polastri, T. F., Martin, C. Y. B. S., Hajjar, L. A., et al. (2021). Cooling as an Adjunctive Therapy to Percutaneous Intervention in Acute Myocardial Infarction: COOL-MI InCor Trial. Therapeutic hypothermia and temperature management, 11( 3), 135-144. doi:10.1089/ther.2020.0018
NLM
Dallan LAP, Giannetti NS, Rochitte CE, Polastri TF, Martin CYBS, Hajjar LA, Nicolau JC, Jr MT de O, Dae M, Silva EER da, Kalil Filho R. Cooling as an Adjunctive Therapy to Percutaneous Intervention in Acute Myocardial Infarction: COOL-MI InCor Trial [Internet]. Therapeutic hypothermia and temperature management. 2021 ; 11( 3): 135-144.[citado 2024 maio 01 ] Available from: https://doi.org/10.1089/ther.2020.0018
Vancouver
Dallan LAP, Giannetti NS, Rochitte CE, Polastri TF, Martin CYBS, Hajjar LA, Nicolau JC, Jr MT de O, Dae M, Silva EER da, Kalil Filho R. Cooling as an Adjunctive Therapy to Percutaneous Intervention in Acute Myocardial Infarction: COOL-MI InCor Trial [Internet]. Therapeutic hypothermia and temperature management. 2021 ; 11( 3): 135-144.[citado 2024 maio 01 ] Available from: https://doi.org/10.1089/ther.2020.0018
Artigo de periodico
Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 (2021)
Lawler, Patrick R; Golighe, Ewan C; Berge, Jeffrey S; Neal, Matthew D; Mcverry, Bryan J; Nicolau, Jose Carlos ; Gong, Michelle N; Carrier, Marc; Rosenson, Robert S; Reynolds, Harmony R
Source: New england journal of medicine. Unidade: FM
Subjects: COVID-19, TROMBOSE, ANTICOAGULANTES, PREVENÇÃO DE DOENÇA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
LAWLER, Patrick R et al. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New england journal of medicine, v. 385, n. 9, p. 790-802, 2021Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa2105911. Acesso em: 01 maio 2024.
APA
Lawler, P. R., Golighe, E. C., Berge, J. S., Neal, M. D., Mcverry, B. J., Nicolau, J. C., et al. (2021). Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19. New england journal of medicine, 385( 9), 790-802. doi:10.1056/NEJMoa2105911
NLM
Lawler PR, Golighe EC, Berge JS, Neal MD, Mcverry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 790-802.[citado 2024 maio 01 ] Available from: https://doi.org/10.1056/NEJMoa2105911
Vancouver
Lawler PR, Golighe EC, Berge JS, Neal MD, Mcverry BJ, Nicolau JC, Gong MN, Carrier M, Rosenson RS, Reynolds HR. Therapeutic Anticoagulation with Heparin in Noncritically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 790-802.[citado 2024 maio 01 ] Available from: https://doi.org/10.1056/NEJMoa2105911
Artigo de periodico
Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 (2021)
Goligher, Ewan C; Bradbury, Charlotte A; Mcverry, Bryan J; Lawler, Patrick R; Berger, Jeffrey S; Gong, Michelle N; Carrier, Marc; Reynolds, Harmony R; Kumar, Anand; Nicolau, Jose Carlos
Source: New england journal of medicine. Unidade: FM
Subjects: COVID-19, TROMBOSE, ANTICOAGULANTES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GOLIGHER, Ewan C et al. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New england journal of medicine, v. 385, n. 9, p. 777-789, 2021Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa2103417. Acesso em: 01 maio 2024.
APA
Goligher, E. C., Bradbury, C. A., Mcverry, B. J., Lawler, P. R., Berger, J. S., Gong, M. N., et al. (2021). Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19. New england journal of medicine, 385( 9), 777-789. doi:10.1056/NEJMoa2103417
NLM
Goligher EC, Bradbury CA, Mcverry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Nicolau JC. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 777-789.[citado 2024 maio 01 ] Available from: https://doi.org/10.1056/NEJMoa2103417
Vancouver
Goligher EC, Bradbury CA, Mcverry BJ, Lawler PR, Berger JS, Gong MN, Carrier M, Reynolds HR, Kumar A, Nicolau JC. Therapeutic Anticoagulation with Heparin in Critically Ill Patients with Covid-19 [Internet]. New england journal of medicine. 2021 ; 385( 9): 777-789.[citado 2024 maio 01 ] Available from: https://doi.org/10.1056/NEJMoa2103417
Artigo de periodico
Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial (2020)
Kosiborod, Mikhail N ; Jhund, Pardeep S; Docherty, Kieran F; Diez, Mirta; Petrie, Mark C; Verma, Subodh; Nicolau, Jose Carlos ; Merkely, Bela; Kitakaze, Masafumi; Demets, David L
Source: Circulation. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, QUALIDADE DE VIDA, BIOMARCADORES, HIDROCARBONOS AROMÁTICOS, DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
KOSIBOROD, Mikhail N et al. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial. Circulation, v. 141, n. 2, p. 90-99, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.044138. Acesso em: 01 maio 2024.
APA
Kosiborod, M. N., Jhund, P. S., Docherty, K. F., Diez, M., Petrie, M. C., Verma, S., et al. (2020). Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial. Circulation, 141( 2), 90-99. doi:10.1161/CIRCULATIONAHA.119.044138
NLM
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, Demets DL. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial [Internet]. Circulation. 2020 ; 141( 2): 90-99.[citado 2024 maio 01 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Vancouver
Kosiborod MN, Jhund PS, Docherty KF, Diez M, Petrie MC, Verma S, Nicolau JC, Merkely B, Kitakaze M, Demets DL. Effects of Dapagliflozin on Symptoms, Function, and Quality of Life in Patients With Heart Failure and Reduced Ejection Fraction Results From the DAPA-HF Trial [Internet]. Circulation. 2020 ; 141( 2): 90-99.[citado 2024 maio 01 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044138
Artigo de periodico
Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF (2020)
Martinez, Felipe A; Serenelli, Matteo; Nicolau, Jose Carlos ; Petrie, Mark C; Chiang, Chern-En; Tereshchenko, Sergey; Solomon, Scott D; Inzucchi, Silvio E; Kober, Lars; Kosiborod, Mikhail N
Source: Circulation. Unidade: FM
Subjects: INSUFICIÊNCIA CARDÍACA, HIDROCARBONOS AROMÁTICOS, FATORES ETÁRIOS, RESULTADO DE TRATAMENTO, ENSAIO CLÍNICO CONTROLADO RANDOMIZADO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
MARTINEZ, Felipe A et al. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF. Circulation, v. 141, n. 2, p. 100-111, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.119.044133. Acesso em: 01 maio 2024.
APA
Martinez, F. A., Serenelli, M., Nicolau, J. C., Petrie, M. C., Chiang, C. -E., Tereshchenko, S., et al. (2020). Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF. Circulation, 141( 2), 100-111. doi:10.1161/CIRCULATIONAHA.119.044133
NLM
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF [Internet]. Circulation. 2020 ; 141( 2): 100-111.[citado 2024 maio 01 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044133
Vancouver
Martinez FA, Serenelli M, Nicolau JC, Petrie MC, Chiang C-E, Tereshchenko S, Solomon SD, Inzucchi SE, Kober L, Kosiborod MN. Efficacy and Safety of Dapagliflozin in Heart Failure With Reduced Ejection Fraction According to Age Insights From DAPA-HF [Internet]. Circulation. 2020 ; 141( 2): 100-111.[citado 2024 maio 01 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.119.044133
Artigo de periodico
Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries (2020)
Brieger, David; Pocockb, Stuart J; Blankenberg, Stefan; Chen, Ji Yan; Cohen, Mauricio G; Granger, Christopher B; Grieve, Richard; Nicolau, Jose Carlos ; Simon, Tabassome; Westermann, Dirk
Source: International journal of cardiology. Unidade: FM
Subjects: ENVELHECIMENTO, INFARTO DO MIOCÁRDIO, FATORES DE RISCO, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BRIEGER, David et al. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. International journal of cardiology, v. 311, p. 7-14, 2020Tradução . . Disponível em: https://doi.org/10.1016/j.ijcard.2020.01.070. Acesso em: 01 maio 2024.
APA
Brieger, D., Pocockb, S. J., Blankenberg, S., Chen, J. Y., Cohen, M. G., Granger, C. B., et al. (2020). Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries. International journal of cardiology, 311, 7-14. doi:10.1016/j.ijcard.2020.01.070
NLM
Brieger D, Pocockb SJ, Blankenberg S, Chen JY, Cohen MG, Granger CB, Grieve R, Nicolau JC, Simon T, Westermann D. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries [Internet]. International journal of cardiology. 2020 ; 311 7-14.[citado 2024 maio 01 ] Available from: https://doi.org/10.1016/j.ijcard.2020.01.070
Vancouver
Brieger D, Pocockb SJ, Blankenberg S, Chen JY, Cohen MG, Granger CB, Grieve R, Nicolau JC, Simon T, Westermann D. Two-year outcomes among stable high-risk patients following acute MI. Insights from a global registry in 25 countries [Internet]. International journal of cardiology. 2020 ; 311 7-14.[citado 2024 maio 01 ] Available from: https://doi.org/10.1016/j.ijcard.2020.01.070
Artigo de periodico
Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial (2020)
Houston, Brett L; Lawler, Patrick R; Goligher, Ewan C; Farkouh, Michael E; Bradbury, Charlotte; Carrier, Marc; Dzavik, Vlad; Fergusson, Dean A; Fowler, Robert A; Nicolau, Jose Carlos
Source: Clinical trials. Unidade: FM
Subjects: ADULTOS, ANTICOAGULANTES, TROMBOSE, RESULTADO DE TRATAMENTO, PANDEMIAS, COVID-19
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
HOUSTON, Brett L et al. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clinical trials, v. 17, n. 5, p. 491-500, 2020Tradução . . Disponível em: https://doi.org/10.1177/1740774520943846. Acesso em: 01 maio 2024.
APA
Houston, B. L., Lawler, P. R., Goligher, E. C., Farkouh, M. E., Bradbury, C., Carrier, M., et al. (2020). Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial. Clinical trials, 17( 5), 491-500. doi:10.1177/1740774520943846
NLM
Houston BL, Lawler PR, Goligher EC, Farkouh ME, Bradbury C, Carrier M, Dzavik V, Fergusson DA, Fowler RA, Nicolau JC. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial [Internet]. Clinical trials. 2020 ; 17( 5): 491-500.[citado 2024 maio 01 ] Available from: https://doi.org/10.1177/1740774520943846
Vancouver
Houston BL, Lawler PR, Goligher EC, Farkouh ME, Bradbury C, Carrier M, Dzavik V, Fergusson DA, Fowler RA, Nicolau JC. Anti-Thrombotic Therapy to Ameliorate Complications of COVID-19 (ATTACC): Study design and methodology for an international, adaptive Bayesian randomized controlled trial [Internet]. Clinical trials. 2020 ; 17( 5): 491-500.[citado 2024 maio 01 ] Available from: https://doi.org/10.1177/1740774520943846
Artigo de periodico
Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF (2020)
Docherty, Kieran F; Jhund, Pardeep S; Anand, Inder; Bengtsson, Olof; Bohm, Michael; Boer, Rudolf A. de; Demets, David L; Desai, Akshay S; Drozdz, Jaroslaw; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: ENVELHECIMENTO, MÉTODO DUPLO-CEGO, INSUFICIÊNCIA CARDÍACA, PACIENTES AMBULATORIAIS, ESTUDOS RETROSPECTIVOS, HEMODINÂMICA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
DOCHERTY, Kieran F et al. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF. Circulation, v. 142, n. 17, p. 1623-1632, 2020Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.120.047480. Acesso em: 01 maio 2024.
APA
Docherty, K. F., Jhund, P. S., Anand, I., Bengtsson, O., Bohm, M., Boer, R. A. de, et al. (2020). Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF. Circulation, 142( 17), 1623-1632. doi:10.1161/CIRCULATIONAHA.120.047480
NLM
Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, Boer RA de, Demets DL, Desai AS, Drozdz J, Nicolau JC. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF [Internet]. Circulation. 2020 ; 142( 17): 1623-1632.[citado 2024 maio 01 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047480
Vancouver
Docherty KF, Jhund PS, Anand I, Bengtsson O, Bohm M, Boer RA de, Demets DL, Desai AS, Drozdz J, Nicolau JC. Effect of dapagliflozin on outpatient worsening of patients with heart failure and reduced ejection fraction a prespecified analysis of DAPA-HF [Internet]. Circulation. 2020 ; 142( 17): 1623-1632.[citado 2024 maio 01 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.120.047480
Artigo de periodico
Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease (2019)
Furtado, Remo H. M; Giugliano, Robert P; Dalcoquio, Talia F; Arantes, Flavia B. B; Barbosa, Carlos J. D. G; Genestreti, Paulo R. R; Franci, Andre; Menezes, Fernando R; Nakashima, Carlos A. K; Nicolau, Jose Carlos
Source: Journal of thrombosis and thrombolysis. Unidade: FM
Subjects: VASOS CORONÁRIOS, ÍNDICE DE MASSA CORPORAL, PESOS E MEDIDAS CORPORAIS, INFARTO DO MIOCÁRDIO, MORTE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
FURTADO, Remo H. M et al. Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. Journal of thrombosis and thrombolysis, v. 48, n. 2, p. 217-224, 2019Tradução . . Disponível em: https://doi.org/10.1007/s11239-019-01830-z. Acesso em: 01 maio 2024.
APA
Furtado, R. H. M., Giugliano, R. P., Dalcoquio, T. F., Arantes, F. B. B., Barbosa, C. J. D. G., Genestreti, P. R. R., et al. (2019). Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease. Journal of thrombosis and thrombolysis, 48( 2), 217-224. doi:10.1007/s11239-019-01830-z
NLM
Furtado RHM, Giugliano RP, Dalcoquio TF, Arantes FBB, Barbosa CJDG, Genestreti PRR, Franci A, Menezes FR, Nakashima CAK, Nicolau JC. Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease [Internet]. Journal of thrombosis and thrombolysis. 2019 ; 48( 2): 217-224.[citado 2024 maio 01 ] Available from: https://doi.org/10.1007/s11239-019-01830-z
Vancouver
Furtado RHM, Giugliano RP, Dalcoquio TF, Arantes FBB, Barbosa CJDG, Genestreti PRR, Franci A, Menezes FR, Nakashima CAK, Nicolau JC. Increased bodyweight and inadequate response to aspirin in individuals with coronary artery disease [Internet]. Journal of thrombosis and thrombolysis. 2019 ; 48( 2): 217-224.[citado 2024 maio 01 ] Available from: https://doi.org/10.1007/s11239-019-01830-z
Artigo de periodico
Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial (2018)
Nicolau, Jose Carlos
Source: Clinical cardiology. Unidade: FM
Subjects: TERAPIA BIOLÓGICA, ESTUDOS RANDOMIZADOS, INFARTO DO MIOCÁRDIO, BETA-BLOQUEADORES
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NICOLAU, Jose Carlos. Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial. Clinical cardiology, v. 41, n. 3, p. 392-399, 2018Tradução . . Disponível em: https://doi.org/10.1002/clc.22882. Acesso em: 01 maio 2024.
APA
Nicolau, J. C. (2018). Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial. Clinical cardiology, 41( 3), 392-399. doi:10.1002/clc.22882
NLM
Nicolau JC. Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial [Internet]. Clinical cardiology. 2018 ; 41( 3): 392-399.[citado 2024 maio 01 ] Available from: https://doi.org/10.1002/clc.22882
Vancouver
Nicolau JC. Stem-cell therapy in ST-segment elevation myocardial infarction with reduced ejection fraction: A multicenter, double-blind randomized trial [Internet]. Clinical cardiology. 2018 ; 41( 3): 392-399.[citado 2024 maio 01 ] Available from: https://doi.org/10.1002/clc.22882
Artigo de periodico-carta/editorial
Gravidez em Portadora de Doença de Kawasaki com Múltiplos Aneurismas de Artérias Coronárias [Editorial] (2018)
Avila, Walkiria Samuel; Freire, Antonio Fernando Diniz; Soares, Alexandre Anderson de Sousa; Pereira, Ana Neri Rodrigues Epitacio; Nicolau, Jose Carlos
Source: Arquivos Brasileiros de Cardiologia. Unidade: FM
Subjects: COMPLICAÇÕES CARDIOVASCULARES NA GRAVIDEZ, VASOS CORONÁRIOS, ANEURISMA CORONÁRIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
AVILA, Walkiria Samuel et al. Gravidez em Portadora de Doença de Kawasaki com Múltiplos Aneurismas de Artérias Coronárias [Editorial]. Arquivos Brasileiros de Cardiologia. Rio De Janeiro: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.5935/abc.20170185. Acesso em: 01 maio 2024. , 2018
APA
Avila, W. S., Freire, A. F. D., Soares, A. A. de S., Pereira, A. N. R. E., & Nicolau, J. C. (2018). Gravidez em Portadora de Doença de Kawasaki com Múltiplos Aneurismas de Artérias Coronárias [Editorial]. Arquivos Brasileiros de Cardiologia. Rio De Janeiro: Faculdade de Medicina, Universidade de São Paulo. doi:10.5935/abc.20170185
NLM
Avila WS, Freire AFD, Soares AA de S, Pereira ANRE, Nicolau JC. Gravidez em Portadora de Doença de Kawasaki com Múltiplos Aneurismas de Artérias Coronárias [Editorial] [Internet]. Arquivos Brasileiros de Cardiologia. 2018 ; 110( 1): 97-100.[citado 2024 maio 01 ] Available from: https://doi.org/10.5935/abc.20170185
Vancouver
Avila WS, Freire AFD, Soares AA de S, Pereira ANRE, Nicolau JC. Gravidez em Portadora de Doença de Kawasaki com Múltiplos Aneurismas de Artérias Coronárias [Editorial] [Internet]. Arquivos Brasileiros de Cardiologia. 2018 ; 110( 1): 97-100.[citado 2024 maio 01 ] Available from: https://doi.org/10.5935/abc.20170185
Artigo de periodico
Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial (2018)
Corbalan, Ramon; Nicolau, Jose Carlos
Source: Journal of the american college of cardiology. Unidade: FM
Subjects: ANTICOAGULANTES, FIBRILAÇÃO ATRIAL, ACIDENTE VASCULAR CEREBRAL, AMÉRICA LATINA
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
CORBALAN, Ramon e NICOLAU, Jose Carlos. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial. Journal of the american college of cardiology, v. 72, n. 13, p. 1466-1475, 2018Tradução . . Disponível em: https://doi.org/10.1016/j.jacc.2018.07.037. Acesso em: 01 maio 2024.
APA
Corbalan, R., & Nicolau, J. C. (2018). Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial. Journal of the american college of cardiology, 72( 13), 1466-1475. doi:10.1016/j.jacc.2018.07.037
NLM
Corbalan R, Nicolau JC. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial [Internet]. Journal of the american college of cardiology. 2018 ; 72( 13): 1466-1475.[citado 2024 maio 01 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.037
Vancouver
Corbalan R, Nicolau JC. Edoxaban versus warfarin in Latin American Patients with atrial fibrillation the ENGAGE AF-TIMI 48 trial [Internet]. Journal of the american college of cardiology. 2018 ; 72( 13): 1466-1475.[citado 2024 maio 01 ] Available from: https://doi.org/10.1016/j.jacc.2018.07.037
Artigo de periodico
Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) (2018)
Giugliano, Robert P.; Nicolau, Jose Carlos
Source: Circulation. Unidade: FM
Subjects: DIABETES MELLITUS, DOENÇAS CARDIOVASCULARES, FÁRMACOS DO SANGUE E SISTEMA HEMATOPOÉTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIUGLIANO, Robert P. e NICOLAU, Jose Carlos. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, v. 137, n. 15, p. 1571-0, 2018Tradução . . Disponível em: https://doi.org/10.1161/CIRCULATIONAHA.117.030950. Acesso em: 01 maio 2024.
APA
Giugliano, R. P., & Nicolau, J. C. (2018). Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial). Circulation, 137( 15), 1571-0. doi:10.1161/CIRCULATIONAHA.117.030950
NLM
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 maio 01 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Vancouver
Giugliano RP, Nicolau JC. Benefit of Adding Ezetimibe to Statin Therapy on Cardiovascular Outcomes and Safety in Patients With Versus Without Diabetes Mellitus Results From IMPROVE-IT (Improved Reduction of Outcomes: Vytorin Efficacy International Trial) [Internet]. Circulation. 2018 ; 137( 15): 1571-0.[citado 2024 maio 01 ] Available from: https://doi.org/10.1161/CIRCULATIONAHA.117.030950
Artigo de periodico
Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial (2018)
Bohula, Erin A.; Scirica, Benjamin M; Inzucchi, Silvio E; Mcguire, Darren K; Keech, Anthony C; Smith, Steven R; Kanevsky, Estella; Murphy, Sabina A; Leiter, Lawrence A; Nicolau, Jose Carlos
Source: Lancet. Unidade: FM
Subjects: DIABETES MELLITUS NÃO INSULINO-DEPENDENTE, OBESIDADE, SOBREPESO, RECEPTORES DE SUBSTÂNCIAS ENDÓGENAS
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BOHULA, Erin A. et al. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, v. 392, n. 10161, p. 2269-2279, 2018Tradução . . Disponível em: https://doi.org/10.1016/S0140-6736(18)32328-6. Acesso em: 01 maio 2024.
APA
Bohula, E. A., Scirica, B. M., Inzucchi, S. E., Mcguire, D. K., Keech, A. C., Smith, S. R., et al. (2018). Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial. Lancet, 392( 10161), 2269-2279. doi:10.1016/S0140-6736(18)32328-6
NLM
Bohula EA, Scirica BM, Inzucchi SE, Mcguire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Nicolau JC. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial [Internet]. Lancet. 2018 ; 392( 10161): 2269-2279.[citado 2024 maio 01 ] Available from: https://doi.org/10.1016/S0140-6736(18)32328-6
Vancouver
Bohula EA, Scirica BM, Inzucchi SE, Mcguire DK, Keech AC, Smith SR, Kanevsky E, Murphy SA, Leiter LA, Nicolau JC. Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial [Internet]. Lancet. 2018 ; 392( 10161): 2269-2279.[citado 2024 maio 01 ] Available from: https://doi.org/10.1016/S0140-6736(18)32328-6
Parte de monografia/livro
Síndromes coronárias agudas (2016)
Giraldez, Roberto Rocha C. V.; Serrano Filho, Carlos Vicente; Nicolau, Jose Carlos
Source: Clínica Médica/vol. 2. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA (DIAGNÓSTICO), CARDIOPATIAS, INFARTO DO MIOCÁRDIO, ANGINA INSTÁVEL, TROMBOSE
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
GIRALDEZ, Roberto Rocha C. V. e SERRANO FILHO, Carlos Vicente e NICOLAU, Jose Carlos. Síndromes coronárias agudas. Clínica Médica/vol. 2. Tradução . Barueri, SP: Manole, 2016. . . Acesso em: 01 maio 2024.
APA
Giraldez, R. R. C. V., Serrano Filho, C. V., & Nicolau, J. C. (2016). Síndromes coronárias agudas. In Clínica Médica/vol. 2. Barueri, SP: Manole.
NLM
Giraldez RRCV, Serrano Filho CV, Nicolau JC. Síndromes coronárias agudas. In: Clínica Médica/vol. 2. Barueri, SP: Manole; 2016. [citado 2024 maio 01 ]
Vancouver
Giraldez RRCV, Serrano Filho CV, Nicolau JC. Síndromes coronárias agudas. In: Clínica Médica/vol. 2. Barueri, SP: Manole; 2016. [citado 2024 maio 01 ]
Artigo de periodico
Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial (2015)
Nicolau, Jose Carlos; Bhatt, Deepak L.; Roe, Matthew T.; Lokhnygina, Yuliya; Neely, Benjamin; Corbalán, Ramón; Leiva-Pons, José L.; Martinez, Felipe; Goodman, Shaun G.; Winters, Kenneth J.; Verheugt, Freek W.A.; Armstrong, Paul W.; White, Harvey D.; Fox, Keith A. A.; Prabhakaran, Dorairaj; Ohman, E. Magnus
Source: American Heart Journal. Unidade: FM
Subjects: SÍNDROME CORONARIANA AGUDA, MEDICAMENTO (ADMINISTRAÇÃO E DOSAGEM), ADMINISTRAÇÃO DOS CUIDADOS AO PACIENTE, RESULTADO DE TRATAMENTO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NICOLAU, Jose Carlos et al. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. American Heart Journal, v. 170, n. 4, p. 683-694, 2015Tradução . . Disponível em: https://doi.org/10.1016/j.ahj.2015.05.017. Acesso em: 01 maio 2024.
APA
Nicolau, J. C., Bhatt, D. L., Roe, M. T., Lokhnygina, Y., Neely, B., Corbalán, R., et al. (2015). Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial. American Heart Journal, 170( 4), 683-694. doi:10.1016/j.ahj.2015.05.017
NLM
Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbalán R, Leiva-Pons JL, Martinez F, Goodman SG, Winters KJ, Verheugt FWA, Armstrong PW, White HD, Fox KAA, Prabhakaran D, Ohman EM. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial [Internet]. American Heart Journal. 2015 ; 170( 4): 683-694.[citado 2024 maio 01 ] Available from: https://doi.org/10.1016/j.ahj.2015.05.017
Vancouver
Nicolau JC, Bhatt DL, Roe MT, Lokhnygina Y, Neely B, Corbalán R, Leiva-Pons JL, Martinez F, Goodman SG, Winters KJ, Verheugt FWA, Armstrong PW, White HD, Fox KAA, Prabhakaran D, Ohman EM. Concomitant proton-pump inhibitor use, platelet activity, and clinical outcomes in patients with acute coronary syndromes treated with prasugrel versus clopidogrel and managed without revascularization: Insights from the Targeted Platelet Inhibition to Clarify the Optimal Strategy to Medically Manage Acute Coronary Syndromes trial [Internet]. American Heart Journal. 2015 ; 170( 4): 683-694.[citado 2024 maio 01 ] Available from: https://doi.org/10.1016/j.ahj.2015.05.017
Trabalho de evento-resumo periodico
Exercise training restores sympathetic response during exercise in patients with Acute Coronary Syndrome and Gln27Glu β2-adrenoceptor polymorphism (2015)
Santos, Larissa; Martinez, Daniel; Nicolau, Jose Carlos; Graner, Humberto; Alves, Maria; Pereira, Alexandre; Trombetta, Ivani; Negrão, C. E.; Rondon, M. U.
Source: FASEB Journal. Conference titles: Experimental Biology. Unidades: FM, EEFE
Subjects: TREINAMENTO FÍSICO (TERAPIA), SÍNDROME CORONARIANA AGUDA, POLIMORFISMO, SISTEMA NERVOSO SIMPÁTICO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
SANTOS, Larissa et al. Exercise training restores sympathetic response during exercise in patients with Acute Coronary Syndrome and Gln27Glu β2-adrenoceptor polymorphism. FASEB Journal. Bethesda: Faculdade de Medicina, Universidade de São Paulo. Disponível em: http://www.fasebj.org/content/29/1_Supplement/831.7.abstract?sid=df031bcb-40b2-4d5e-a869-47bdbd285b92. Acesso em: 01 maio 2024. , 2015
APA
Santos, L., Martinez, D., Nicolau, J. C., Graner, H., Alves, M., Pereira, A., et al. (2015). Exercise training restores sympathetic response during exercise in patients with Acute Coronary Syndrome and Gln27Glu β2-adrenoceptor polymorphism. FASEB Journal. Bethesda: Faculdade de Medicina, Universidade de São Paulo. Recuperado de http://www.fasebj.org/content/29/1_Supplement/831.7.abstract?sid=df031bcb-40b2-4d5e-a869-47bdbd285b92
NLM
Santos L, Martinez D, Nicolau JC, Graner H, Alves M, Pereira A, Trombetta I, Negrão CE, Rondon MU. Exercise training restores sympathetic response during exercise in patients with Acute Coronary Syndrome and Gln27Glu β2-adrenoceptor polymorphism [Internet]. FASEB Journal. 2015 ; 29( 1):[citado 2024 maio 01 ] Available from: http://www.fasebj.org/content/29/1_Supplement/831.7.abstract?sid=df031bcb-40b2-4d5e-a869-47bdbd285b92
Vancouver
Santos L, Martinez D, Nicolau JC, Graner H, Alves M, Pereira A, Trombetta I, Negrão CE, Rondon MU. Exercise training restores sympathetic response during exercise in patients with Acute Coronary Syndrome and Gln27Glu β2-adrenoceptor polymorphism [Internet]. FASEB Journal. 2015 ; 29( 1):[citado 2024 maio 01 ] Available from: http://www.fasebj.org/content/29/1_Supplement/831.7.abstract?sid=df031bcb-40b2-4d5e-a869-47bdbd285b92
Artigo de periodico-carta/editorial
Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes (2014)
Bianco, Henrique T.; Izar, Maria C.; Póvoa, Rui M.; Bombig, Maria T.; Fonseca, Henrique A.; Helfenstein, Tatiane; Ferreira, Carlos Eduardo; Nicolau, Jose Carlos; Afiune Neto, Abrahão; Feio, Claudine Maria; Cerci, Mario Sergio; Fonseca, Francisco A.
Source: International Journal of Cardiology. Unidade: FM
Subjects: HIPERTROFIA VENTRICULAR ESQUERDA, DIABETES MELLITUS, MORTALIDADE, ELETROCARDIOGRAFIA, BRASIL
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
BIANCO, Henrique T. et al. Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes. International Journal of Cardiology. Amsterdan: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1016/j.ijcard.2014.07.251. Acesso em: 01 maio 2024. , 2014
APA
Bianco, H. T., Izar, M. C., Póvoa, R. M., Bombig, M. T., Fonseca, H. A., Helfenstein, T., et al. (2014). Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes. International Journal of Cardiology. Amsterdan: Faculdade de Medicina, Universidade de São Paulo. doi:10.1016/j.ijcard.2014.07.251
NLM
Bianco HT, Izar MC, Póvoa RM, Bombig MT, Fonseca HA, Helfenstein T, Ferreira CE, Nicolau JC, Afiune Neto A, Feio CM, Cerci MS, Fonseca FA. Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes [Internet]. International Journal of Cardiology. 2014 ; 176 1170-1172.[citado 2024 maio 01 ] Available from: https://doi.org/10.1016/j.ijcard.2014.07.251
Vancouver
Bianco HT, Izar MC, Póvoa RM, Bombig MT, Fonseca HA, Helfenstein T, Ferreira CE, Nicolau JC, Afiune Neto A, Feio CM, Cerci MS, Fonseca FA. Left ventricular hypertrophy and QTc dispersion are predictors of long-term mortality in subjects with type 2 diabetes [Internet]. International Journal of Cardiology. 2014 ; 176 1170-1172.[citado 2024 maio 01 ] Available from: https://doi.org/10.1016/j.ijcard.2014.07.251
Artigo de periodico
Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST (II Edição, 2007) - Atualização 2013/2014 (2014)
Nicolau, Jose Carlos; Timerman, A; Marin Neto, Jose Antonio; Piegas, L. S; Barbosa, C. J. D. G; Franci, A; Avezum Junior, A; Carvalho, A. C. C; Markman Filho, B; Polanczyk, C. A; Rochitte, C. E; Serrano Junior, Carlos Vicente; Precoma, D. B; Silva Junior, D. G; Albuquerque, D. C; Stefanini, E; Knobel, E; Jatene, Fábio Biscegli; Feres, F; Morcerf, F. A. P; Ganem, F; Lima Filho, F. A; Feitosa Filho, G. S; Ferreira, J. F. M; Meneghetti, J. C; Saraiva, J. F. K; Silva, L. S; Maia, L. N; Baracioli, L. M; Lisboa, L. A. F; Dallan, Luís Alberto Oliveira; Bodanese, L. C; Andrade, M. D; Oliveira Júnior, M; Dutra, O. P; Coelho, O. R; Leães, P. E; Albuquerque, P. F; Lemos, P; Kalil, R; Costa, R. V. C; Esporcate, R; Marino, R. L; Botellho, R. V; Meneghelo, R. S; Sprovieri, S. R; Timerman, S; Mathias Júnior, W
Source: Arquivos Brasileiros de Cardiologia. Unidades: FM, FMRP
Subjects: DOENÇAS CARDIOVASCULARES (PREVENÇÃO E CONTROLE), ANGINA INSTÁVEL, INFARTO DO MIOCÁRDIO
A citação é gerada automaticamente e pode não estar totalmente de acordo com as normas
ABNT
NICOLAU, Jose Carlos et al. Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST (II Edição, 2007) - Atualização 2013/2014. Arquivos Brasileiros de Cardiologia, v. 102, n. 3, p. 1-61, 2014Tradução . . Disponível em: https://doi.org/10.5935/abc.2014S001. Acesso em: 01 maio 2024.
APA
Nicolau, J. C., Timerman, A., Marin Neto, J. A., Piegas, L. S., Barbosa, C. J. D. G., Franci, A., et al. (2014). Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST (II Edição, 2007) - Atualização 2013/2014. Arquivos Brasileiros de Cardiologia, 102( 3), 1-61. doi:10.5935/abc.2014S001
NLM
Nicolau JC, Timerman A, Marin Neto JA, Piegas LS, Barbosa CJDG, Franci A, Avezum Junior A, Carvalho ACC, Markman Filho B, Polanczyk CA, Rochitte CE, Serrano Junior CV, Precoma DB, Silva Junior DG, Albuquerque DC, Stefanini E, Knobel E, Jatene FB, Feres F, Morcerf FAP, Ganem F, Lima Filho FA, Feitosa Filho GS, Ferreira JFM, Meneghetti JC, Saraiva JFK, Silva LS, Maia LN, Baracioli LM, Lisboa LAF, Dallan LAO, Bodanese LC, Andrade MD, Oliveira Júnior M, Dutra OP, Coelho OR, Leães PE, Albuquerque PF, Lemos P, Kalil R, Costa RVC, Esporcate R, Marino RL, Botellho RV, Meneghelo RS, Sprovieri SR, Timerman S, Mathias Júnior W. Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST (II Edição, 2007) - Atualização 2013/2014 [Internet]. Arquivos Brasileiros de Cardiologia. 2014 ; 102( 3): 1-61.[citado 2024 maio 01 ] Available from: https://doi.org/10.5935/abc.2014S001
Vancouver
Nicolau JC, Timerman A, Marin Neto JA, Piegas LS, Barbosa CJDG, Franci A, Avezum Junior A, Carvalho ACC, Markman Filho B, Polanczyk CA, Rochitte CE, Serrano Junior CV, Precoma DB, Silva Junior DG, Albuquerque DC, Stefanini E, Knobel E, Jatene FB, Feres F, Morcerf FAP, Ganem F, Lima Filho FA, Feitosa Filho GS, Ferreira JFM, Meneghetti JC, Saraiva JFK, Silva LS, Maia LN, Baracioli LM, Lisboa LAF, Dallan LAO, Bodanese LC, Andrade MD, Oliveira Júnior M, Dutra OP, Coelho OR, Leães PE, Albuquerque PF, Lemos P, Kalil R, Costa RVC, Esporcate R, Marino RL, Botellho RV, Meneghelo RS, Sprovieri SR, Timerman S, Mathias Júnior W. Diretrizes da Sociedade Brasileira de Cardiologia sobre Angina Instável e Infarto Agudo do Miocárdio sem Supradesnível do Segmento ST (II Edição, 2007) - Atualização 2013/2014 [Internet]. Arquivos Brasileiros de Cardiologia. 2014 ; 102( 3): 1-61.[citado 2024 maio 01 ] Available from: https://doi.org/10.5935/abc.2014S001

USP Schools

ReP

Filtros

Document Types

USP Schools

Departament

Authors

USP affiliated authors

Date published

Subjects

Source title

Conference titles

Countries/Territories

Funding Agencies

Indexado em

Non normalized affiliation

Countries of institutions of collaboration